Vitafoods europe 2024: at Bioiberica we pave the way for innovation in mobility with the new Collavant® n2 clinical data in healthy population
At Bioiberica, we will be shining a spotlight on new cutting-edge clinical research behind our native type II collagen, Collavant® n2 (40 mg/ day) at Vitafoods Europe (14-16 May, Geneva, Switzerland). Noteworthy findings from the highly anticipated trial are set to be presented for the first time at the Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis, taking place this week on 18-21 April. Visitors to the company’s stand (F142) at Vitafoods Europe will then have the unique opportunity to discuss the remarkable discoveries with our experts at Bioiberica – including results showing that 40 mg/day Collavant® n2 significantly alleviates joint discomfort after exercise; underscoring its potential to enhance consumers’ daily lives. Attendees can speak to our team to uncover how the scientific insights can be translated into appealing supplements for the mobility sphere, and more.
Collavant® n2 shows promise in healthy individuals for first time
Our latest Bioiberica clinical trial, conducted in collaboration with the Poal Institute of Rheumatology in Barcelona, Spain, set out to evaluate the efficacy and tolerability of Collavant® n2 on the joint function of healthy volunteers experiencing joint discomfort post-intensive exercise. Over a six-month period, participants took either 40 mg/day of Collavant® n2 native (undenatured) type II collagen or a placebo, and several parameters were assessed at intervals of 60, 90, 120 and 180 days using KOOS (Knee Injury and Osteoarthritis Outcome Score). The outcomes revealed a significant reduction in joint discomfort on day 120 and an improvement in quality of life from day 90 versus baseline in the Collavant® n2 group. In subjects with basal activity-related discomfort (VAS < 4cm), we detected statistically significant improvements versus placebo at day 180 for both joint discomfort and quality of life. Moreover, Collavant® n2 consistently supported faster recovery from discomfort after exercise, during the trial – significantly outperforming the placebo group at day 180.
Ingrid Möller MD, PhD – Rheumatologist at Poal Institute of Rheumatology in Barcelona and lead investigator of the trial – commented: “This marks the first exploration of Collavant® n2’s effects in healthy individuals, and not just those with joint health conditions. In my view, native type II collagen is a pro-health nutritional solution and this research confirms my belief that it could be beneficial for ‘everyday consumers’ leading active lifestyles or regularly engaged in sports; a demographic that continues to grow.”
Daniel Martínez-Puig, Head of R&D Human and Animal Health at Bioiberica and another key investigator of the study remarked: “This research could be a gamechanger in the field of nutrition innovation. Not only were the initial findings promising, but the positive effects of Collavant® n2 were observed after just three months. This suggests the ingredient could therefore contribute to overall satisfaction and compliance with products featuring it.”
Daniel will present the study’s key insights during Vitafoods Europe (14-16 May, Geneva, Switzerland) at the New Ingredients Theatre (F184) on Wednesday 15 May, at 15.30 CET.
Meet Bioiberica at Vitafoods Europe 2024
In addition to our Collavant® n2 research, at this year’s exhibition, at Bioiberica we are excited to share the latest news behind our other flagship branded ingredients for skin health (Dermial®), joint and muscle support (Mobilee®) and digestive wellness (DAOgest), and how they’re helping to empower the health evolution. We will also reveal our contributions to sustainability in the Life Science sector – providing insights about its Environmental, Sustainable & Governance (ESG) framework, dedicated to advancing our sustainability initiatives, including ambitions to achieve climate neutrality by 2050. Our team will be on hand to share more details about the company’s recent efforts to achieve two new Sustainable Development Goals (SDGs) this year, as part of our ongoing efforts to support One Health - a multisectoral worldwide health strategy that recognises the interactions and interdependencies between human, animal and environmental health.
For more information about Bioiberica’s healthcare portfolio, or to schedule a meeting with the team at Vitafoods Europe, please visit: www.bioiberica.com
These statements have not been evaluated by competent food authorities. The product is not intended to diagnose, treat, cure, or prevent any disease. This information is only for business-to-business use and not meant to be addressed to final consumers.